34 institutions hold shares in Aerpio Pharmaceuticals Inc. (ARPO), with 7.66M shares held by insiders accounting for 16.18% while institutional investors hold 49.55% of the company’s shares. The shares outstanding are 47.17M, and float is at 45.16M with Short Float at 2.68%. Institutions hold 41.53% of the Float.
The top institutional shareholder in the company is Satter Management Company, LP with over 5.62 million shares valued at $5.51 million. The investor’s holdings represent 13.85% of the ARPO Shares outstanding. As of Dec 30, 2020, the second largest holder is Orbimed Advisors LLC. with 5.19 million shares valued at $5.09 million to account for 12.80% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 2.71 million shares representing 6.68% and valued at over $2.66 million, while Renaissance Technologies, LLC holds 4.43% of the shares totaling 1.8 million with a market value of $1.76 million.
Aerpio Pharmaceuticals Inc. (NASDAQ: ARPO) is 33.67% higher on its value in year-to-date trading and has touched a low of $0.47 and a high of $2.31 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARPO stock was last observed hovering at around $1.49 in the last trading session, with the day’s loss setting it -0.18% off its average median price target of $2.00 for the next 12 months. It is also 34.5% off the consensus price target high of $2.00 offered by 2 analysts, but current levels are 34.5% higher than the price target low of $2.00 for the same period.
Currently trading at $1.31, the stock is -18.86% and -18.83% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.22 million and changing -12.08% at the moment leaves the stock -9.09% off its SMA200. ARPO registered 151.92% gain for a year compared to 6-month gain of -7.09%. The firm has a 50-day simple moving average (SMA 50) of $1.7291 and a 200-day simple moving average (SMA200) of $1.4756.
The stock witnessed a -26.40% loss in the last 1 month and extending the period to 3 months gives it a 24.76%, and is -20.61% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.63% over the week and 9.74% over the month.
Aerpio Pharmaceuticals Inc. (ARPO) has around 12 employees, a market worth around $66.56M and $15.00M in sales. Profit margin for the company is -28.80%. Distance from 52-week low is 175.79% and -43.29% from its 52-week high. The company has generated returns on investments over the last 12 months (-14.70%).
Aerpio Pharmaceuticals Inc. (ARPO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Aerpio Pharmaceuticals Inc. (ARPO) is a “Overweight”. 2 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Aerpio Pharmaceuticals Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.1.The EPS is expected to grow by 82.30% this year.
Aerpio Pharmaceuticals Inc. (ARPO) Insider Activity
A total of 2 insider transactions have happened at Aerpio Pharmaceuticals Inc. (ARPO) in the last six months, with sales accounting for 1 and purchases happening 1 times. The most recent transaction is an insider sale by ORBIMED ADVISORS LLC, the company’s 10% Owner. SEC filings show that ORBIMED ADVISORS LLC sold 21,400 shares of the company’s common stock on Dec 08 at a price of $1.96 per share for a total of $41944.0. Following the sale, the insider now owns 0.0 shares.
Aerpio Pharmaceuticals Inc. (ARPO): Who are the competitors?
Omeros Corporation (OMER) is 63.60% up on the 1-year trading charts. Short interest in the company’s stock has fallen -11.57% from the last report on Feb 11, 2021 to stand at a total of 1.35 million short shares sold with a short interest ratio of 0.89.